Tracers to monitor the response to chemotherapy: in vitro screening of four radiopharmaceuticals. by Geus-Oei, L.F. de et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
 CANCER BIOTHERAPY & RADIOPHARMACEUTICALS
Volume 19, Number 4, 2004
' Mary Ann Liebert, Inc.
Tracers to Monitor the Response to Chemotherapy:
In Vitro Screening of Four Radiopharmaceuticals
Lioe-Fee de Geus-Oei,1 Jullitte van Eerd-Vismale,1 Carla Molthoff,2 Frans Corstens,1
Wim Oyen,1 and Otto Boerman1
1Department of Nuclear Medicine, University Medical Center, Nijmegen, The Netherlands
2PET Center/Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands
ABSTRACT
Objectives: It has been postulated that radiopharmaceuticals can be used to predict the therapeutic re-
sponse to (chemo)therapy, which could lead to individualized treatment regimens. In this study, 18F-de-
oxyglucose, 99mTc-tetrofosmin, 125I-deoxyuridineribose, and 125I-methyltyrosine were tested for this pur-
pose. Methods: The uterine sarcoma cell line MES-SA (MDR2) and its multidrug resistant variant,
MES-SA/Dx5 (MDR1), were used. The MDR1 cells express high levels of P-glycoprotein, which makes
them relatively resistant to various chemotherapeutic agents. Cells were cultured in the presence of es-
calating concentrations of doxorubicin, and the cellular uptake of the radiopharmaceuticals was deter-
mined. Results: Decreasing 18F-deoxyglucose uptake at escalating doxorubicin concentrations reflected
the chemosensitivity of the cells: 18F-deoxyglucose uptake in the MDR2 cells was reduced to 40% of the
baseline level in the presence of 1 mM of doxorubicin, compared to 74% in the MDR1 cells. The 125I-
deoxyuridineribose uptake in MDR2 cells was reduced to 2% of the baseline level when cultured at a
concentration of 1 mM of doxorubicin, while this was 79% in the MDR1 cells. The same trend was ob-
served with 125I-methyltyrosine. The enhanced doxorubicin chemosensitivity of MDR1 cells in the pres-
ence of verapamil, a modulator of P-glycoprotein, was reflected by the reduced uptake of 18F-deoxyglu-
cose, 125I-deoxyuridineribose, and 125I-methyltyrosine. Furthermore, baseline 99mTc-tetrofosmin uptake in
MDR1 cells was more than six-fold lower than in MDR2 cells. Conclusion: In the presence of doxoru-
bicin, the uptake of 18F-deoxyglucose, 125I-deoxyuridineribose and, to a lesser extent, 125I-methyltyrosine
is more pronouncedly reduced in MDR2 cells than in MDR1 cells. The reversal of doxorubicin-resis-
tance of MDR1 cells by verapamil was also reflected by the uptake of 18F-deoxyglucose, 125I-de-
oxyuridineribose, and 125I-methyltyrosine. 99mTc-tetrofosmin uptake reflected P-glycoprotein expression
without exposure to doxorubicin.




One of the major problems in the treatment of
cancer with chemotherapeutics is the develop-
ment of multidrug resistance (MDR) by tumor
Address reprint requests to: Lioe-Fee de Geus-Oei; De-
partment of Nuclear Medicine (internal postal code 565),
University Medical Center Nijmegen; P.O. Box 9101, NL-
6500 HB Nijmegen, The Netherlands; Tel.: 131-24-
3614048; Fax: 131-24-3618942
E-mail: L.degeus-oei@nucmed.umcn.nl
5171_e08_p457-465  9/6/04  9:10 AM  Page 457
cells. It is of great clinical importance to identify
those patients that will respond to particular an-
ticancer agents and, therefore, to avoid unneces-
sary toxicity, (effective) therapy delay, and ex-
pense in nonresponsive patients. Particularly in
the case of newer biological treatments involving
cytostatic (in contrast to cytolytic) drugs, an ex-
tended period of observation is often required be-
fore significant changes in the patientÕs clinical
status, or in the radiographic evaluations, are ob-
served. Therefore, there is a need for a relevant
measure of treatment response that could identify
treatment ÒsuccessÓ or ÒfailureÓ much earlier than
changes in tumor size or volume identified with
computed tomography (CT) or magnetic reso-
nance (MR). An early assessment of treatment re-
sponse is critical in designing appropriate and in-
dividualized treatment regimens.1
Various mechanisms are responsible for mul-
tidrug resistance, one of the most important being
the overexpression of a plasma membrane phos-
phoglycoprotein, P-glycoprotein (P-gp), which is
encoded by the MDR1 gene. P-gp is the transporter
protein responsible for actively pumping cytotoxic
agents out of the cell. Besides P-gp, alternative in-
tracellular mechanisms of resistance have been re-
ported, including intracellular entrapment, com-
partmentalization or redistribution by the multidrug
resistance-associated protein (MRP) and the lung-
resistant protein (LRP), enhanced drug detoxifica-
tion by glutathion-S transferase, changes in levels
or activity of nuclear targets, such as topoisomerase
II, and alterations in the control of apoptosis.2 Be-
cause the overexpression of P-gp is the most im-
portant mechanism responsible for MDR, we fo-
cused on P-gp in this study.
The distribution of P-gp in many organs sug-
gests that the expression of P-gp is actually a
physiological protection mechanism of the human
body. P-gp can provide protection by extruding
toxins out of the cells into urine, bile, and the in-
testinal lumen. It appears to protect critical organs,
such as the brain and the testes, against toxic com-
pounds. The MDR1 gene expressed in several
normal human tissues, is associated with secre-
tory or barrier functions, and in some bone mar-
row and blood cells.3 Overexpression of P-gp may
result in increased excretion and decreased reten-
tion of various MDR substrates, and thus de-
creased cytotoxic efficacy of anticancer agents.4
Chemotherapeutic agents such as anthracy-
clines (daunorubicin and doxorubicin), vinca al-
kaloids (vincristine and vinblastine), epipodo-
phyllotoxins (etoposide), and taxanes (paclitaxel)
are all substrates for P-gp and are extruded out
of the cell by P-gp. Besides chemotherapeutic
drugs, several other drugs are substrates for P-gp,
such as cardiovascular drugs (verapamil and
digoxin), and immunosuppressives (cyclosporin
A, PSC833). It is not yet clearly understood by
what mechanism P-gp is able to recognize such
diverse compounds, and, most likely, more than
one drug binding site is involved.5,6
It is of great relevance to identify patients with
MDR resulting from overexpression of P-gp. De-
tection of protein and RNA expression for the
MDR1 pump can be performed in human tumor
samples using a variety of techniques, such as im-
munohistochemistry, quantitative autoradiography,
and reverse transcriptase polymerase chain reac-
tion.7—10 However, detection of P-gp does not nec-
essarily provide any information about the function
of these pumps in the respective tissues. Further-
more, serial tumor biopsies are not generally per-
formed. Radiotracers that can visualize the activity
of cellular efflux pumps noninvasively are, there-
fore, of interest. In addition, various radiopharma-
ceuticals can potentially be used to predict the ther-
apeutic response to chemotherapy. In our study, we
studied 4 radiopharmaceuticals (18F-deoxyglucose
(5FDG), 99mTc-tetrofosmin (5TF), 125I-methylty-
rosine (5IMT), and 125I-deoxyuridineribose
(5IUdR)) for their ability to monitor the response
of cancer cells to doxorubicin treatment.
The experiments were performed in the pres-
ence and absence of the calcium channel blocker
verapamil, a potent modulator of P-gp. To inhibit
P-gp-mediated extrusion of chemotherapeutic
agents, this modulator can be used beside other
modulators, such as the immunosuppressive
agent cyclosporin A and PSC833.11 Verapamil
most likely acts by binding competitively to bind-
ing sites on the MDR transport proteins or by al-
tering the affinities of the recognition domains in
those proteins.12 Being informed about the effect
of a modulator on both tumor tissue and normal
tissues in each individual patient before starting
chemotherapy could be clinically useful. This
may help to select patients who will eventually




The cell line MES-SA 1976 (ATCC, CRL-1976)
and its multidrug resistant variant, MES-SA/Dx5
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1977 (ATCC, CRL-1977) were used in these ex-
periments. The development and characterization
of the human uterine sarcoma cell line MES-SA
and its multistep-selected MDR variant Dx5 cells
have been described elsewhere.14,15 In brief,
wild-type MES-SA 1976 (P-gp-negative) cells
were derived from a human uterine sarcoma.
MES-SA/Dx5 1977 (P-gp-positive) cells were
derived from MES-SA 1976 cells grown in the
presence of increasing doxorubicin concentra-
tions. As a result of doxorubicin exposure, MES-
SA/Dx5 1977 cells express high levels of MDR1
RNA and P-gp (but not MRP), and are relatively
resistant to doxorubicin, as well as to various
other chemotherapeutic agents. Doxorubicin re-
sistance in this cell line is stable, despite long pe-
riods of growth in a drug-free medium.
Radiopharmaceuticals
18Fluoro-2-deoxy-D-glucose (FDG)
18Fluoro-2-deoxy-D-glucose was obtained com-
mercially from Tyco Health B.V., Petten, The
Netherlands.
99mTc-Tetrofosmin (TF)
Tetrofosmin kits were obtained commercially
(Myoview¤, Amersham Healthcare, Bucking-
hamshire, England UK). The labeling and qual-
ity control procedures were carried out according
to the manufacturers instructions. The radio-
chemical purity of TF used in this study was con-
sistently higher than 95%.
125I-Iodo-methyl-tyrosine (IMT)
Synthesis of IMT was carried out essentially as de-
scribed by Krummeich et al.16 133 mL of Iodogen
(0.75 mg/mL) was added in a glass reaction vial
(Iodogen tube), and the chloroform was evapo-
rated under a stream of nitrogen. 400 mL 0.11 M
borate buffer, pH 8.0, and 90 mL of L-alpha-
methyl tyrosine (Sigma-Aldrich Chemie b.v., Zwi-
jndrecht, The Netherlands) dissolved in 0.22 M bo-
rate buffer, pH 1.7, were added. Subsequently,
200—250 mCi of Na-125I was added. The reaction
was allowed to proceed for 10 minutes at room
temperature. The reaction mixture was transferred
into a 1.5-mL vial and 250 mL of Na2S2O5 (2
mg/mL) in 0.11 M borate buffer, pH 8.0, was
added. A Sep-Pak C-18 cartridge (Waters Corpo-
ration, Milford, MA) was activated with 15 mL of
ethanol and rinsed with 15 mL 5% ethanol in 0.9%
NaCl. The reaction mixture was loaded onto the
conditioned Sep-Pak cartridge. The Sep-Pak car-
tridge was eluted with 13 mL 5% ethanol in 0.9%
NaCl, and fractions of 1 mL were collected. The
carrier-free IMT eluted in the fraction 4-6. The
RCP of the IMT was analyzed using an HPLC sys-
tem with C-18 column (Zorbax Rx-C18, 4.6 3 25
cm) equipped with a radiodetector. H2O/etha-
nol/acetic acid (92.5/5/2.5) was used as eluens with
a flow of 0.5 mL/min. Rf values were: L-a-methyl
tyrosine precursor, 2.75 minutes (UV 280 nm),
free 125I 3.1 min and 125I-IMT product, 10.1 min.
Radiochemical yield was higher than 95%, with a
specific activity of 3612 GBq/mol.
5-[125I]Iodo-29-deoxyuridine (IUdR)
Noncarrier-added sterile 5-[125I]Iodo-29-deoxy-
uridine (IUdR) (specific activity 74 TBq/mmol)
was purchased from Amersham International
(Buckinghamshire, England UK).
Drugs
Doxorubicin hydrochloride was obtained as
Adriblastina RTU (2 mg/mL for injection) (Phar-
macia and Upjohn, Woerden, The Netherlands).
It was stored at 4¡C and protected from light. Ve-
rapamil hydrochloride (2.5 mg/mL) was pur-
chased from Knoll AG, BASF Pharma, Lud-
wigshafen, Germany.
In Vitro Assay
Cells were cultured at 37¡C, 5% CO2, in RPMI-
1640 (Gibco, Life Technologies, Gaithersburg,
MD) with 10% fetal calf serum (FCS) and 2 mM
glutamine, using 162 cm2 culture flasks. Cells
(105 cells/mL) were seeded in 24-well plates. The
aim of the first series of experiments was to de-
termine the optimal doxorubicin incubation
schedule. Doxorubicin (escalating concentrations
0—1000 mM) was added starting at 72, 48, and 24
hours before the addition of the radiopharma-
ceuticals, as presented in Figure 1. Subsequently,
the medium was removed from the wells, and
cells were washed twice with saline. To each
well, 106 cpm/mL (1 mL/well) 125I-de-
oxyuridineribose in RPMI-1640 1 0.5% BSA
(Gibco, Invitrogen, Breda, The Netherlands),
125I-methyltyrosine in RPMI-1640 1 0.5% BSA,
18F-deoxyglucose in glucose-free-DMEM 1
0.5% BSA or 99mTc-tetrofosmin in RPMI-
1640 1 0.5% BSA, respectively, was added. Af-
ter 1 hour of incubation at 37¡C, cells were
washed, swabbed, and counted in a well-type
gamma counter. The mean cell-associated activ-
459
5171_e08_p457-465  9/6/04  9:10 AM  Page 459
ity of each of the radiopharmaceuticals following
incubation in the absence of doxorubicin was set
at 100%. The uptake at the various doxorubicin
concentrations was expressed as the percentage
of this activity.
MTT Assay
In order to investigate whether tracer uptake in-
deed reflected cell proliferation, the mitochon-
drial dehydrogenase activity and, hence, cell sur-
vival, was measured using the MTT assay
(3-[4.5-dimethylthiazol-2-yl]-2.5-diphenyltetra-
zolium bromide, Thiazolyl blue [Sigma Chemi-
cal Co., St. Louis, MO). Dissolved MTT is con-
verted to an insoluble purple formazan by
cleavage of the tetrazolium ring by mitochon-
drial dehydrogenases of viable cells, and the ab-
sorbance of the solubilized formazan solution is
proportional to the number of viable cells. Cell
surivival of both cell lines (MES-SA 1976 and
MES-SA/Dx5 1977) at doxorubicin concentra-
tions of 0—1 mM, was expressed relative to their
controls in the absence of any treatment. Cells
were seeded into 24-well plates (in triplicate) at
a density of approximately 3 3 104 cells per well
in RPMI-1640, with 10% FCS and 2 mM gluta-
mine for 48 hours. At 48 hours, the medium was
replaced by doxorubicin (concentrations 0—1
mM) in RPMI-1640 for an exposure period of 48
hours. Then, cells were washed with saline, and
the MTT stock solution (5 mg/mL in RPMI-1640
without phenol red with 10% FCS and 2 mM glu-
tamine) was added to each well (320 mL/well)
and incubated for 5 hours at 37¡C. At the end of
the incubation period, the medium was removed,
cells were washed twice with saline, and the con-
verted dye was solubilized with 1 mL 0.01 N
HCl/10% SDS during 16 hours at 37 ¡C. Ab-
sorbance of converted dye was measured at a
wavelength of 570 nm.
RESULTS
MTT Assay
MTT results provide evidence that 48 hours of
exposure to doxorubicin could induce repro-
ducible cell death at escalating doxorubicin con-
centrations (0—1 mM) to an increasing extent,
with an obvious difference between the MDR2
cells and MDR1 cells. Measurements of relative
cell survival compared to untreated control cells
showed that doxorubicin induced 80% cell death
at 1 mM in the MDR2 cells, compared to only
5% at 1 mM in the MDR1 cells.
Experiments to Determine the Most Optimal
Incubation Scheme
The aim of the first series of experiments was to
determine the schedule to expose cancer cells to
doxorubicin that would lead to the most pro-
nounced effect on the uptake of each of the ra-
diopharmaceuticals. Figure 2 demonstrates the
results of the 5 different doxorubicin incubation
schemes measured with FDG. The most pro-
nounced difference in reduction of FDG uptake
between the MDR1 and MDR2 cell line at low
doxorubicin dose levels (0.1—1.0 (mM) was seen
with the incubation schemes 2, 3, and 4. This also
applied for IMT and IUdR. Based on these ob-
servations, scheme number 4 (48 hours doxoru-
bicin exposure, followed by 1 hour incubation
with each of the radiopharmaceuticals) was cho-
sen for future experiments. In this scheme, there
is no delay between incubation with doxorubicin
and addition of radiopharmaceuticals, avoiding
tumor-cell recovery.
The FDG uptake at escalating doxorubicin
doses (Fig. 2) correlated with the chemosensitiv-
ity of the cells: FDG uptake of the MDR2 cells
declined at lower doxorubicin concentrations,
compared to that of MDR1 cells. To reach the
same reduction of FDG uptake, a 10-fold higher
doxorubicin concentration was needed in the
MDR1 cells. Higher doxorubicin levels (.100
(mM) were cytotoxic to both cell lines, regard-
less of their chemosensitivity.
The results from the IUdR and IMT experi-
ments showed an even more pronounced effect
(Fig. 3). In the chemosensitive cells, IUdR up-
take was reduced to zero at a 100-fold lower dose
460
Figure 1. Schematic representation of the incubation
schemes of doxorubicin (escalating concentrations of
0—1000 mM) used in the in vitro experiments.
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than the chemoresistant cells (1 mM compared to
100 mM). With IMT, this was almost a 1,000-
fold (1 mM, compared to 1,000 mM).
99mTc-Tetrofosmin (TF) differed from the
other three radiotracers in some aspects. Because
the amount of uptake of this tracer reflects the P-
gp activity, there is no need to expose the cells
to doxorubicin in the assay. In order to measure
P-gp activity, just the percentage of uptake of TF
in the absence of doxorubicin are of interest.
Baseline TF uptake of the MDR1 cells was more
than sixfold lower compared to that in MDR2
cells, presumably resulting from enhanced P-gp
activity of MDR1 cells.
Effects of Verapamil
In the second series of experiments, the effect of
the P-gp antagonist verapamil on the effect of dox-
orubicin on tracer uptake was investigated. In the
first experiment, a suitable verapamil concentration
was determined for these experiments. Both cell
lines were incubated with escalating verapamil con-
centrations (1—125 mg/mL) in the absence of dox-
orubicin (Fig. 4). At the two highest verapamil con-
centrations tested (25 and 125 mg/mL), the FDG
uptake of the cells was reduced and, therefore, 5
mg/mL verapamil was used in further experiments.
Subsequently, the effect of verapamil (5
mg/mL) on cell viability at various doxorubicin
concentrations was tested in the MTT assay (Fig.
5). Verapamil had only a limited effect on the
number of viable cells. In the presence of vera-
pamil, the MDR1 cells were more susceptible to
high concentrations of doxorubicin (10—100
mM). Interestingly, the number of MDR2 cells
at low doxorubicin concentrations (0.1—1 mM)























































































Figure 2. These graphs demonstrate the results of the 5 different doxorubicin incubation schemes, as shown in Figure 1, mea-
sured with FDG.
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slightly affected cell viability when cultured in
the presence of doxorubicin.
In contrast, the reversal of the drug-resistance
by verapamil was clearly reflected by the uptake
of FDG, IUdR, and IMT. Fig 6A shows that FDG
uptake in the MDR1 cells was markedly reduced
because of the presence of verapamil. In fact,
based on the FDG uptake the MDR1 cells be-
came almost as sensitive to doxorubicin as the
MDR2 cells. The uptake of FDG was markedly
reduced in the MDR1 cells when verapamil was
coincubated: from 79% to 18% at 1.0 mM dox-
orubicin. Although less pronounced, this effect of
verapamil was also observed with the MDR2
cells: from 48% to 3% at 1.0 mM doxorubicin.
The same trend was observed with IUdR and IMT
(Fig. 6B and 6C). The effects on TF uptake were
less apparant (Fig. 7). In the absence of vera-
pamil, the uptake of TF was 0.13% ID in the
MDR1 cells, compared to 0.87% ID in the
MDR2 cells, whereas in the presence of vera-
pamil these values were 0.19% ID and 1.43% ID,
respectively.
DISCUSSION
The results of this study show that 18Fluoro-2-
deoxy-D-glucose (5FDG), 5-[125I]Iodo-29-de-
oxyuridine (5IUdR), and 125I-Iodo-methyl-tyro-
sine (5IMT) uptake is more pronouncedly re-
duced after exposure to doxorubicin in MES-SA
cells that are drug-sensitive, as compared to
MES-SA cells that are drug-resistant. The differ-
ence between the sensitive and resistant cell line
was displayed most pronouncedly by IUdR. The
results from the MTT assay showed that tracer
uptake reflected cell viability. Exposure to doxo-
rubicin induced a reduction in cell mitochondrial
dehydrogenase activity, which was more pro-
nounced in the MDR2 cells. In these assays, the
radiopharmaceuticals FDG, IMT, and IUdR had
similar features. First, all showed a clear dis-
crimination in uptake pattern between the sensi-
tive and the resistant cell line. Second, the effect
was reversed by the addition of a P-gp-modula-
tor. The three radiopharmaceuticals also had var-
ious distinctive features, which makes each of
them unique.
Radiopharmaceuticals originally developed
for diagnosis of cardiac viability could be used
as a sensitive tool for the detection of MDR.
99mTc-tetrofosmin (5 TF) was the first radio-
tracer studied for this application. As compared
to FDG, IMT, and IUdR, TF potentially has the
advantage that it can be used before starting che-




































Figure 3. Results of doxorubicin incubation scheme 4 (see Figure 1). Measurements with 125I-methyltyrosine (A) and 125IUdR
(B).
Figure 4. Effect of the verapamil concentration on the
FDG uptake of MDR2 and MDR1 cells.
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cals reflect the change in cell metabolism or pro-
liferating activity after exposure to doxorubicin,
which is essentially different from TF-accumu-
lation, which is based on functional imaging of
P-gp. Our results show that a reduced intracel-
lular accumulation of TF is seen in resistant
cells, as compared to their drug-sensitive coun-
terpart. Unexpectedly, the reduced uptake of TF
in MDR1 cells was only minimally enhanced
when verapamil was coincubated. Possibly be-
cause of the relatively high P-gp expression on
these cells, verapamil could not effectively en-
hance intracellular TF accumulation. Interest-
ingly, the MTT assay showed that coincubation
of verapamil hardly affected the number of vi-
able cells. In contrast, the cellular uptake of
FDG, IMT, and IUdR was markedly reduced
when verapamil was added, indicating that ver-
apamil reduced the metabolic functions of the
cells (glycolytic acitivity, aminoacid transport,
and DNA synthesis, respecitively) rather than
affecting the number of cells.
18Fluoro-2-deoxy-D-glucose (5FDG) was cho-
sen as an indicator for cell metabolic activity.
FDG enters normal and malignant cells using the
same transport mechanisms as glucose and is
trapped intracellularly because of its low de-
phosphorylation rate. The increased rate of gly-
colysis in tumor cells enhances the uptake of
FDG relative to normal cells. The therapeutic ef-
fectiveness of cancer treatment by radiotherapy
and chemotherapy is usually evaluated by mor-
phologic changes in tumor size examined by X-
ray studies, CT, ultrasound, or MRI. An advan-
tage of FDG-PET over these anatomic-structure
imaging modalities, is the ability to distinguish
active or recurrent disease and residual scar tis-
sue after therapy. The most important advantage
of FDG is that metabolic alterations of tumor
cells, indicative of tumor response to therapy,
may occur before alterations in tumor size. Our
results show that FDG is able to differentiate be-
tween the MDR1 cells and MDR2 cells, i.e.,
463
Figure 6. 18FDG-, 125IUdR-, and 125I-methyltyrosine up-
take at escalating doxorubicin doses in MDR2 and MDR1
cells in the presence and absence of verapamil.
Figure 5. Effect of verapamil (5 mg/mL) on the cell
numbers following incubation at escalating doxoru-
bicin concentrations, as measured in the MTT assay.
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FDG uptake decreased more pronouncedly in the
responding cells. Studies on small numbers of pa-
tients suggest that FDG uptake decreases in re-
sponding lesions, although a correlation between
FDG uptake and the P-gp status of tumors has
not yet been established.17—21
Another relevant target for functional tumor
imaging is the uptake of amino acid analogs in can-
cer cells for which radiolabeled amino acids, such
as 125I-Iodo-methyl-tyrosine (5IMT), can be ap-
plied. It is known that IMT shows a favorable nor-
mal distribution. Physiological low uptake is found
in the brain, liver, and spleen, but intense uptake
in the kidneys and urinary system, as it is renally
excreted.22 The results of our in vitro experiments
showed that the suppression of cell proliferation
by doxorubicin can be measured using IMT.
The potential for obtaining functional images
of DNA synthesis using PET and SPECT has
been recognized for some time.23 Halogenated
thymidine analogs such as IUdR can be used as
cell proliferation markers for in vitro studies be-
cause these compounds are rapidly incorporated
into newly synthesized DNA. In vivo, the use of
IUdR is limited as a result of the moderate im-
age quality and the inaccurate calculation of pro-
liferation rates, because of its rapid in vivo degra-
dation. The C—N glycosidic bond of IUdR is not
stable in vivo, which leads to metabolites with re-
duced tumor affinity.24 The attractive aspect of
IUdR is that the uptake of IUdR reflects DNA
synthesis and, hence, the proliferative status of
tumors and normal tissues. In our experiments,
IUdR displayed the most marked relative reduc-
tion in MES-SA cells that respond to exposure to
doxorubicin, as compared to FDG and IMT.
Clinically, it is also important to detect and
evaluate multidrug resistance transporter activity
in tumors, as this could also be utilized as a tool
in identifying patients who may benefit from
combined therapy with P-gp or multidrug resis-
tance-associated protein (MRP) modulators, as
well as in the evaluation of the effectiveness of
such treatment in vivo. It might also allow for the
selection of the proper modulator for the indi-
vidual patient. A number of drugs have been iden-
tified (e.g., calcium channel blockers, antiar-
rhythmics, antidepressants, and many others) that
can reverse P-gp-mediated MDR. These drugs
(e.g., verapamil, quinidine, and cyclosporin A)
sensitize MDR tumor cells to coadministered cy-
totoxic agents. However, many of them are of
limited clinical use because of side effects in the
relevant doses.25 Clinical trials of inhibitors have
often been hampered by the inability to document
multidrug resistance in solid tumors of individ-
ual patients.26 It may be valuable to assess the ef-
fect of a modulator on both tumor tissue and nor-
mal tissues in each individual patient prior to
treatment, not only to choose the most effective
modulator or combination of modulators in clin-
ical trails, but also to determine the most effec-
tive dose combined with the least toxicity of an-
ticancer drugs. Response to doxorubicin was
affected by the presence, or absence, of vera-
pamil. This could clearly be measured with FDG
and IMT, as well as with IUdR. However, in con-
trast to other studies,27 in our study, verapamil
did not dramatically increase the accumulation of
TF in the MDR1 cells.
CONCLUSION
This study shows that FDG, IUdR, and IMT up-
take is more pronouncedly reduced in MES-SA
cells that respond to exposure to doxorubicin than
in cells that do not. IUdR displayed the most
markedly relative reduction. Unlike these three ra-
diopharmaceuticals, TF shows these differences
before exposure to doxorubicin, reflecting the ex-
pression of the MDR1 gene. The P-gp modulator,
verapamil, is able to reverse the doxorubicin re-
sistance, which could be measured with 3 out of
4 radiopharmaceuticals. These findings warrant
comparative studies in in vivo tumor models.
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